CardioMEMS is an emerging company which has developed BioMEMS technology for treatment of Abdominal Aortic Aneurysm (AAA) and Heart Failure (HF) disease. The company announced last month that it has completed its series C round of financing, raising $16 million of equity funding.
Medtronic, a new investor, led the round and previous investors Boston Millennia Partners, Foundation Medical Partners, Johnson & Johnson Development Corporation, Guidant Corporation, and Arboretum Ventures also participated. Briefly prior to that, CardioMEMS announced the FDA clearance and U.S. market launch of the company’s EndoSure™ Wireless AAA Pressure Measurement System.
We recently spoke with CardioMEMS’ President and CEO David Stern.